🔎 Trials Near Me

Почетна › Рак на бели дробови со не-мали клетки › Орегон › Portland

Клинички испитувања за Рак на бели дробови со не-мали клетки во Portland, OR

46 студии за Рак на бели дробови со не-мали клетки бараат учесници на локации во и околу Portland (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.

Официјален текст на студијата (англиски)

Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Се регрутираФаза 3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Kaiser Permanente Northwest, Portland
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Се регрутираФаза 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Providence Willamette Falls Medical Center, Oregon City · на 12 милји
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Се регрутираФаза 1/2
  • Oregon Health & Science University (OHSU), Portland
Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Се регрутираФаза 1
  • Exelixis Clinical Site #51, Portland
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT05176483

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Се регрутираФаза 3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Oregon Health and Science University, Portland
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06498635

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Се регрутираФаза 1
  • Site 02, Portland
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07814248

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Се регрутираФаза 1
  • ALX Center 6, Portland
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07085091

A Study of PHN-012 in Patients With Advanced Solid Tumors

Се регрутираФаза 1
  • PHN-012-001 Site, Portland
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07127874

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Се регрутираФаза 1
  • Research Site, Portland
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT05877599

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Се регрутираФаза 3
  • OHSU Knight Cancer Institute, Northwest, Portland
  • Providence Cancer Institute Franz Clinic, Portland
  • OHSU Knight Cancer Institute, East Portland, Portland
  • и уште 6
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Се регрутираФаза 3
  • Oregon Health and Science University ( Site 0052), Portland
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06312137

A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

Се регрутираФаза 2
  • Providence Cancer Center, Portland
  • Providence Oncology and Hematology Care Clinic Westside, Portland
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07586202

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Се регрутираФаза 3
  • Northwest Cancer Specialists, P.C., Portland
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07222566

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Се регрутираФаза 2
  • Oregon Health And Science University, Portland
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06667908

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Се регрутираФаза 2
  • Oregon Health And Science University, Portland
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06667076

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Се регрутираФаза 1
  • Research Site, Portland
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06218914

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Се регрутираФаза 3
  • Providence Portland Medical Center, Portland
  • Providence St. Vincent Medical Center, Portland
  • Kaiser Permanente Interstate Medical Office Central, Portland
  • и уште 1
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT06890598

Pan-tumor MRD Study

Се регрутираНабљудувачка студија
  • Oregon Health & Science University (OHSU), Portland
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT06605404

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Се регрутираФаза 1/2
  • Providence Portland Medical Center, Portland
  • Providence St. Vincent Medical Center, Portland
  • Local Institution - 0052, Portland
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT06618287

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Се регрутираФаза 2/3
  • Providence Cancer Institute Franz Clinic, Portland
  • Providence St. Vincent Medical Center, Portland
  • Oregon Health and Science University, Portland
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07100080

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Се регрутираФаза 2
  • Providence Portland Medical Center, Portland
  • Oregon Health and Science University, Portland
Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT06855771

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Се регрутираФаза 3
  • Clinical Study Site, Portland
Возраст 18 и постари · Сите полови · Ажурирано 18.9.2026 · NCT06767514

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Се регрутираФаза 3
  • Providence Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07195695

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Се регрутираФаза 2/3
  • Local Institution - 007-885B, Portland
  • Local Institution - 007-885A, Portland
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT04613596

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Се регрутираФаза 1
  • Providence Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Се регрутираФаза 3
  • Providence Portland Medical Center, Portland
  • Providence St. Vincent Medical Center, Portland
  • Kaiser Permanente Interstate Medical Office Central, Portland
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06119581

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Се регрутираФаза 3
  • Oregon Health and Science University, Portland
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06793215

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Се регрутираФаза 2
  • Providence Portland Medical Center, Portland
Возраст 18 и постари · Сите полови · Ажурирано 26.8.2026 · NCT07288177

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

Се регрутираФаза 3
  • Oregon Health & Science University, Portland
Возраст од 18 до 100 · Сите полови · Ажурирано 19.8.2026 · NCT05317858

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Се регрутираФаза 1/2
  • Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT04895709

A Study of MGC026 in Participants With Advanced Solid Tumors

Се регрутираФаза 1
  • Providence Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 11.8.2026 · NCT06242470

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Се регрутираФаза 1/2
  • Compass Oncology - Rose Quarter, Portland
Возраст 18 и постари · Сите полови · Ажурирано 4.8.2026 · NCT05579366

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Се регрутираФаза 1/2
  • Providence Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 21.7.2026 · NCT05098132

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Се регрутираФаза 1
  • Providence Cancer Institute Franz Clinic, Portland
  • Providence Oncology and Hematology Care Clinic - Westside, Portland
  • Providence St. Vincent Medical Center- Investigational Drug Services, Portland
  • и уште 1
Возраст 18 и постари · Сите полови · Ажурирано 6.7.2026 · NCT04389632

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Се регрутираФаза 2
  • Oregon Health and Science University, Portland
Возраст од 18 до 70 · Сите полови · Ажурирано 26.6.2026 · NCT04614103

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Се регрутираФаза 4
  • OHSU Knight Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 12.6.2026 · NCT07405086

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Се регрутираФаза 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Kaiser Permanente Northwest, Portland
  • и уште 2
Возраст 18 и постари · Сите полови · Ажурирано 3.6.2026 · NCT05642572

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Се регрутираФаза 2
  • USA15-0, Portland
Возраст 18 и постари · Сите полови · Ажурирано 22.5.2026 · NCT06953089

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Се регрутираФаза 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Kaiser Permanente Northwest, Portland
  • и уште 2
Возраст 18 и постари · Сите полови · Ажурирано 6.5.2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Се регрутираФаза 2/3
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Oregon Health and Science University, Portland
  • и уште 1
Возраст 18 и постари · Сите полови · Ажурирано 5.5.2026 · NCT06616584

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Се регрутираФаза 2
  • Providence Health & Services - Oregon, Portland
Возраст 18 и постари · Сите полови · Ажурирано 5.5.2026 · NCT04317534

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Се регрутираФаза 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Kaiser Permanente Northwest, Portland
  • и уште 2
18 Minutes · Сите полови · Ажурирано 5.5.2026 · NCT06031688

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Се регрутираНабљудувачка студија
  • Kaiser Permanente Northwest, Portland
Возраст 18 и постари · Сите полови · Ажурирано 17.3.2026 · NCT06418204

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Се регрутираФаза 1
  • Providence Cancer Institute, Portland
Возраст 18 и постари · Сите полови · Ажурирано 6.3.2026 · NCT06171750

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Се регрутираНабљудувачка студија
  • Massive Bio SYNERGY-AI site, Portland
Сите возрасти · Сите полови · Ажурирано 28.10.2025 · NCT03452774

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Се регрутираФаза 1/2
  • Oregon Health & Science University, Portland
Возраст 18 и постари · Сите полови · Ажурирано 13.2.2025 · NCT05669430

Испитувања за Рак на бели дробови со не-мали клетки во други градови

Други студии во Portland

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.